Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
HOUSTON, May 16, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the EHA2024 Hybrid Congress being held June 13-16, 2024 in Madrid, Spain and virtually.
休斯顿，2024 年 5 月 16 日 — Moleculin Biotech有限公司，（纳斯达克股票代码：MBRX）（“Moleculin” 或 “公司”）是一家临床阶段的制药公司，拥有广泛的针对难以治疗的肿瘤和病毒的候选药物组合，今天宣布其摘要已获准在会上作海报展示 EHA2024 混合大会 将于 2024 年 6 月 13 日至 16 日在西班牙马德里以虚拟方式举行。
Details for the poster presentation are as follows:
海报展示详情如下：
Abstract: P537
Session: Acute myeloid leukemia – Clinical
Title: LIPOSOMAL ANNAMYCIN (L-ANN) IN COMBINATION WITH CYTARABINE FOR TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) REFACTORY TO OR RELAPSED (R/R) AFTER INDUCTION THERAPY (MB-106 STUDY)
Presenting Author: Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin
摘要： P537
会话： 急性髓系白血病 — 临床
标题： 脂质体安那霉素（L-ANN）与阿糖胞苷联合用于治疗诱导治疗后急性髓系白血病（AML）复发或复发（R/R）患者（MB-106 研究）
主讲作者： Wolfram C. M. Dempke，医学博士，工商管理硕士，Moleculin 欧洲首席医学官
For more information about the EHA2024 Hybrid Congress, visit the event website.
有关 EHA2024 混合大会的更多信息，请访问 活动网站。
About Moleculin Biotech, Inc.
关于 Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data discussed above are subject to change.
Moleculin Biotech, Inc. 是一家临床阶段的制药公司，针对难以治疗的肿瘤和病毒的产品线不断扩大，包括二期临床项目。该公司的主要项目安那霉素是下一代蒽环素，旨在避免多药耐药机制，并消除目前处方蒽环类药物常见的心脏毒性。安那霉素目前正在开发中，用于治疗复发或难治性急性髓系白血病（AML）和软组织肉瘤（STS）肺转移。上面讨论的所有中期和初步数据可能会发生变化。
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
此外，该公司正在开发免疫/转录调节剂 WP1066，一种免疫/转录调节剂，能够抑制p-stat3和其他致癌转录因子，同时刺激针对脑肿瘤、胰腺和其他癌症的自然免疫反应，以及用于局部治疗皮肤 T 细胞淋巴瘤的 WP1066 类似物 WP1220。Moleculin 还参与开发抗代谢药物产品组合，包括用于潜在病毒治疗的 WP1122，以及包括脑肿瘤、胰腺癌和其他癌症在内的癌症适应症。
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
如需了解有关公司的更多信息，请访问 www.moleculin.com 然后连接 推特， 领英 和 Facebook。
Investor Contact:
投资者联系人：
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
JTC Team, LLC
珍妮·托马斯
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-abstract-accepted-for-poster-presentation-at-the-european-hematology-association-eha-2024-hybrid-congress-302146725.html
SOURCE Moleculin Biotech, Inc.
来源 Moleculin Biotech, Inc.